Stoke Therapeutics (STOK) Competitors $12.06 -0.26 (-2.11%) (As of 12/13/2024 05:35 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends STOK vs. EWTX, MOR, KYMR, GMTX, KROS, VCEL, IOVA, CPRX, AGIO, and AMRXShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Edgewise Therapeutics (EWTX), MorphoSys (MOR), Kymera Therapeutics (KYMR), Gemini Therapeutics (GMTX), Keros Therapeutics (KROS), Vericel (VCEL), Iovance Biotherapeutics (IOVA), Catalyst Pharmaceuticals (CPRX), Agios Pharmaceuticals (AGIO), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Edgewise Therapeutics MorphoSys Kymera Therapeutics Gemini Therapeutics Keros Therapeutics Vericel Iovance Biotherapeutics Catalyst Pharmaceuticals Agios Pharmaceuticals Amneal Pharmaceuticals Stoke Therapeutics (NASDAQ:STOK) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations. Which has more risk & volatility, STOK or EWTX? Stoke Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Which has stronger earnings & valuation, STOK or EWTX? Edgewise Therapeutics has lower revenue, but higher earnings than Stoke Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$8.78M72.76-$104.70M-$2.10-5.74Edgewise TherapeuticsN/AN/A-$100.16M-$1.50-18.41 Does the MarketBeat Community believe in STOK or EWTX? Stoke Therapeutics received 76 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 74.66% of users gave Stoke Therapeutics an outperform vote while only 73.33% of users gave Edgewise Therapeutics an outperform vote. CompanyUnderperformOutperformStoke TherapeuticsOutperform Votes10974.66% Underperform Votes3725.34% Edgewise TherapeuticsOutperform Votes3373.33% Underperform Votes1226.67% Does the media refer more to STOK or EWTX? In the previous week, Stoke Therapeutics had 9 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 17 mentions for Stoke Therapeutics and 8 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.24 beat Stoke Therapeutics' score of 0.22 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is STOK or EWTX more profitable? Edgewise Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -629.90%. Edgewise Therapeutics' return on equity of -26.83% beat Stoke Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics-629.90% -54.45% -40.77% Edgewise Therapeutics N/A -26.83%-25.67% Do analysts prefer STOK or EWTX? Stoke Therapeutics currently has a consensus price target of $20.83, indicating a potential upside of 72.75%. Edgewise Therapeutics has a consensus price target of $42.33, indicating a potential upside of 53.27%. Given Stoke Therapeutics' higher possible upside, research analysts clearly believe Stoke Therapeutics is more favorable than Edgewise Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Edgewise Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryStoke Therapeutics beats Edgewise Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Donald Trump just won the election resoundingly. And already, in the first few hours after the news, Bitcoin has skyrocketed.This could be his favorite coin. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$638.82M$6.84B$5.25B$9.26BDividend YieldN/A3.04%5.20%4.00%P/E Ratio-5.746.5698.0715.13Price / Sales72.76307.551,356.89144.57Price / CashN/A57.2942.1238.50Price / Book3.385.244.844.87Net Income-$104.70M$151.03M$118.63M$224.77M7 Day Performance-9.12%-5.19%17.63%-0.41%1 Month Performance-13.24%-6.03%19.32%4.01%1 Year Performance132.37%16.27%39.30%23.98% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics4.0986 of 5 stars$12.06-2.1%$20.83+72.7%+132.4%$638.82M$8.78M-5.74100Analyst ForecastInsider TradeNews CoveragePositive NewsEWTXEdgewise Therapeutics3.5676 of 5 stars$30.18-7.4%$42.33+40.3%+290.7%$2.86BN/A-21.7360Options VolumePositive NewsMORMorphoSys0.0879 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730KYMRKymera Therapeutics2.4772 of 5 stars$43.87-6.0%$53.50+22.0%+73.4%$2.84B$78.59M0.00170Analyst ForecastPositive NewsGMTXGemini TherapeuticsN/A$64.82+4.0%N/A+7.4%$2.81BN/A-64.8230KROSKeros Therapeutics3.4718 of 5 stars$68.46-2.2%$93.25+36.2%-37.9%$2.77B$150,000.000.00100Analyst ForecastOptions VolumeNews CoverageGap UpVCELVericel0.8502 of 5 stars$56.10-0.5%$59.71+6.4%+61.5%$2.77B$197.52M939.66300Analyst DowngradePositive NewsIOVAIovance Biotherapeutics4.1587 of 5 stars$8.98-0.6%$22.33+148.7%+6.5%$2.74B$1.19M0.00500Short Interest ↑CPRXCatalyst Pharmaceuticals4.6539 of 5 stars$21.87-0.7%$31.14+42.4%+52.4%$2.61B$398.20M18.66167Insider TradeShort Interest ↑AGIOAgios Pharmaceuticals4.3631 of 5 stars$45.64-26.0%$56.00+22.7%+71.2%$2.60B$26.82M4.57390Analyst ForecastHigh Trading VolumeAMRXAmneal Pharmaceuticals3.1337 of 5 stars$8.16-3.4%$10.00+22.5%+66.2%$2.53B$2.39B0.007,700Positive News Related Companies and Tools Related Companies EWTX Alternatives MOR Alternatives KYMR Alternatives GMTX Alternatives KROS Alternatives VCEL Alternatives IOVA Alternatives CPRX Alternatives AGIO Alternatives AMRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STOK) was last updated on 12/14/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredTrump won. Buy this coin now.Donald Trump just won the election resoundingly. And already, in the first few hours after the news, Bitcoi...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredWall Street Icon: “If you wait on this, it will already be too late”...Investing legend Louis Navellier warned us about the stock market crash of 1987... the 2000 dot-com crash… Enr...InvestorPlace | Sponsored$1 Trillion About to Get Wiped Out Because of this Sneaky Fed Move?The Federal Reserve is sitting on almost $1 TRILLION in unrealized losses. The reason why is that the Fed i...Behind the Markets | SponsoredThis happened before the 1987 crash too…I’d urge you to watch my latest exposé into what’s really going on in the tech sector… why I believe we could ...Porter & Company | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredMedia Is Mocking Elon, But Wait Until They See This DemoElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
